The world looks to the DCRI as the definitive leader in cardiovascular clinical research, implementation science, and education. We look to our practicing faculty, cutting-edge analytics, and operational expertise to address a spectrum of challenges through clinical research focused on improving care and outcomes for patients with cardiovascular disease.

The Next CV Advancement Begins Here

The Cardiovascular Clinical Trials group advances and streamlines the process through innovative study design, fit-for-purpose approaches, thoughtful analytics, and a commitment to rapid knowledge dissemination. This is essential to translate novel therapeutic concepts into effective and efficient clinical trials across the spectrum of cardiovascular illnesses.

CV Outcomes Research

The demand to clearly and quickly demonstrate outcomes of new therapies for cardiovascular patients is greater now than ever before. And the DCRI is the national leader in helping sponsors do that—collecting and analyzing economic and quality-of-life data for the purpose of overcoming barriers to reimbursement.

DCRI’s Health Services Research Outcomes group maintains the world’s oldest and largest ongoing database for cardiovascular disease and is conducting groundbreaking pragmatic clinical trials for patients with heart disease.

With 21 full-time faculty and 100 full-time statisticians, project managers, and research and operational team members, the DCRI Outcomes Research team evaluates outcomes and costs in phase II through IV clinical trials and observational research studies.

Testing for Cardiovascular Devices

The DCRI has a team of experts specifically dedicated to providing critical guidance and support for the unique challenges faced by devices trials, such as evolving regulatory requirements and the need for rapid recruitment of eligible patients.

John Alexander, MD, MHS
Our Clinical Expertise
  • Acute coronary syndromes
  • Antithrombotics/thrombosis
  • Chronic coronary artery disease and coronary atherosclerosis
  • Dyslipidemia and hyperlipidemia
  • Cardiac surgery
  • Cardiovascular genetics and genomics
  • Cardiac diagnostic testing
  • Electrophysiology
  • Atrial fibrillation
  • Pacemakers and implantable defibrillators
  • Antiarrhythmic agents
  • Geriatric cardiology
  • Heart failure
  • Pediatric cardiology
  • Peripheral vascular disease
  • Diabetes mellitus and cardiovascular disease
  • Metabolic disorders
  • Risk modeling for coronary disease
  • Valvular heart disease

DCRI Shares Innovative Research, Thought Leadership at ACC.20

A20316 ACC20WCC Virtual Social Media Graphics_INST1080x1080[2]

DCRI thought leaders shared their knowledge during the joint 2020 ACC Scientific Sessions (ACC) and World Congress of Cardiology (WCC) virtual conference March 28 through March 30. This special format provided visitors to the ACC website with open access to late-breaking clinical trials, high-impact presentations, e-posters, slides on-demand, and more. Visit our DCRI @ACC.20 page to learn how DCRI faculty, fellows, and operations leaders contributed and engaged with this practice-changing clinical research.


Revealing New Insights for Specific Groups of Patients

Results from AUGUSTUS revealed that some patients with coronary artery disease and atrial fibrillation may have better outcomes when they skip aspirin.


Encouraging Cardiologists to Work With Other Providers

COORDINATE-Diabetes, an implementation study led by the DCRI, focuses on helping cardiology clinics to coordinate with endocrinologists and primary care providers when caring for patients with cardiovascular disease and Type 2 diabetes.


Examining How Treatments Are Used in Real-World Practice

The DCRI is working with Amgen to enroll 8,500 patients in a large registry that will enable researchers to examine how PCSK9 inhibitors and other treatments for lipid management are used in real-world practice.

Advancing the Field of Racial Health Disparities in Cardiovascular Research

Kevin Thomas, MD, discusses the ways in which his group attempts to move past describing racial disparities in treatment and outcomes and toward identifying causes of the disparities and interventions that would help bridge the gap, particularly as it pertains to cardiovascular care.

Cardiovascular Leadership at the DCRI 

John H. Alexander, MD, MHS, FACC, Director

John H. Alexander is a cardiologist and professor of medicine in the Department of Medicine and Division of Cardiology at Duke University, as well as the Vice Chief for Clinical Research in the Division of Cardiology. He is the director of cardiovascular research at the DCRI, where he oversees a large group of clinical research faculty and a broad portfolio of cardiovascular clinical trials and other clinical research programs.

Alexander’s clinical interests are in acute and general cardiovascular disease, valvular heart disease, and echocardiology. His research focuses on the translation of novel therapeutic concepts into clinical data through clinical trials, specifically on the therapeutics of acute coronary syndromes and chronic coronary artery disease, on antithrombotic therapies, and on novel methodological approaches to clinical research.

Alexander has published extensively and has served on the steering committee and as the principal investigator of numerous multicenter clinical trials. He serves on the steering committee of the Clinical Trial Transformation Initiative (CTTI).